SCHEMBL30563239

SCHEMBL30563239

C[C@H](NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 3/20 0.67
OPRM1 P35372 2/20 0.67
NPBWR1 P48145 5/20 0.54
ACE P12821 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
LMNA P02545 1/20 0.50
MPO P05164 1/20 0.50
MAPT P10636 1/20 0.50
TSHR P16473 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
KMT2A Q03164 1/20 0.50
HIF1A Q16665 1/20 0.50
CCKBR P32239 5/20 0.49
PRMT1 Q99873 1/20 0.48
ERBB2 P04626 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30834724 0.93 OPRM1 (0.56) OPRD1OPRM1ACEKDM4EMEN1
SCHEMBL29947263 0.91 ACE (0.58) OPRD1OPRM1ACEKDM4EMEN1
SCHEMBL30777843 0.89 OPRD1 (0.70) OPRD1OPRM1NPBWR1ACEKDM4E
Glycine SCHEMBL9868791 0.88 OPRD1 (0.70) OPRD1OPRM1NPBWR1ACEKDM4E
SCHEMBL5970454 0.87 KDM4E (0.62) ACEKDM4EMEN1LMNAMPO
SCHEMBL21641798 0.87 KDM4E (0.62) ACEKDM4EMEN1LMNAMPO
SCHEMBL29493326 0.87 PRMT1 (0.63) OPRD1OPRM1NPBWR1ACEPRMT1
SCHEMBL10749608 0.86 OPRD1 (0.68) OPRD1OPRM1NPBWR1ACEKDM4E
SCHEMBL30169836 0.86 ERAP2 (0.63) NPBWR1ACE
SCHEMBL30405470 0.85 OPRM1 (0.64) OPRD1OPRM1NPBWR1ACEKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12257323-B2 Modified wound dressings CONVATEC TECHNOLOGIES INC. (US) 2025-03-25 US disclosed
US-20240123091-A1 MODIFIED WOUND DRESSINGS CONVATEC TECHNOLOGIES, INC. 2024-04-18 US disclosed
US-11865192-B2 Modified wound dressings CONVATEC TECHNOLOGIES, INC. (US) 2024-01-09 US disclosed
EP-3436012-B1 MODIFIED WOUND DRESSINGS CONVATEC TECHNOLOGIES INC (US) 2023-09-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240123091-A1 MODIFIED WOUND DRESSINGS MMP8, CD68, ELANE OPRD1 3705/4885OPRM1 3161/4885NPBWR1 3551/4885
US-11865192-B2 Modified wound dressings MMP8, CD68, ELANE OPRD1 3705/4885OPRM1 3161/4885NPBWR1 3551/4885
US-12257323-B2 Modified wound dressings MMP8, CD68, ELANE OPRD1 3705/4885OPRM1 3161/4885NPBWR1 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.